^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EBTATE

    i
    Other names: EBTATE, 177Lu-DOTA-EB-TATE, 177Lu-DOTA-EB-TATE 1 , 177Lu-DOTA-EB-TATE 2, 177Lu-DOTA-EB-TATE 3, 177Lu-EBTATE
    Associations

    News

    Trials
    Company:
    Molecular Targeting Tech, National Institutes of Health
    Drug class:
    Ionizing radiation emitter, SSTR2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    15d
    Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors. (PubMed, Eur J Nucl Med Mol Imaging)
    [225Ac]Ac-EBTATE is safe and effective against SCLC and pan-NET and therefore warrants clinical investigation.
    Preclinical • Journal
    |
    SSTR2 (Somatostatin Receptor 2)
    |
    SSTR2 expression • SSTR2 overexpression • SSTR2 underexpression
    |
    EBTATE
    9ms
    Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2-Positive Neuroendocrine Tumors. (PubMed, J Nucl Med)
    The antitumor efficacy of [67Cu]Cu-EB-TATE is comparable to that of [177Lu]Lu-EB-TATE, with [67Cu]Cu-EB-TATE being slightly more effective than [177Lu]Lu-EB-TATE for complete remission of small tumors. [67Cu]Cu-EB-TATE therefore warrants clinical development.
    Journal
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    SSTR2 positive
    |
    EBTATE
    9ms
    177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors (clinicaltrials.gov)
    P1, N=9, Recruiting, Molecular Targeting Technologies, Inc. | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR Expression
    |
    EBTATE
    over2years
    Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Peking Union Medical College Hospital | Unknown status --> Recruiting | N=20 --> 60 | Trial completion date: Dec 2019 --> May 2023 | Trial primary completion date: Dec 2019 --> Dec 2022
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR Expression
    |
    Lutathera (lutetium Lu 177 dotatate) • EBTATE • Solucin (177Lu-edotreotide)
    over2years
    177Lu-DOTA-EB-TATE in Untreated (Naïve) Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors (clinicaltrials.gov)
    P1, N=9, Recruiting, Molecular Targeting Technologies, Inc.
    New P1 trial
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR Expression
    |
    EBTATE